Current Report Filing (8-k)
February 22 2017 - 8:11AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 22, 2017
OCULAR THERAPEUTIX, INC.
(Exact Name of Company as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-36554
|
|
20-5560161
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
34 Crosby Drive, Suite 105
Bedford, MA 01730
(Address of Principal Executive Offices) (Zip Code)
Companys telephone number, including area code: (781) 357-4000
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01 Other Events.
On February 22, 2017, Ocular Therapeutix, Inc. (the Company) announced that the U.S. Food and Drug Administration (the FDA)
accepted for review the Companys new drug application (NDA) resubmission for DEXTENZA (dexamethasone insert) 0.4 mg for the treatment of ocular pain occurring after ophthalmic surgery.
The FDA determined that the NDA resubmission is a complete response and designated the NDA resubmission as a class 2 review with a target action date under
the Prescription Drug User Fee Act of July 19, 2017 for the potential approval of DEXTENZA. The FDA has not confirmed whether a re-inspection of the Companys manufacturing facility will be required as part of its review, but such
re-inspection may still be required.
Forward Looking Statements
Any statements in this filing about future expectations, plans and prospects for the Company, including the development and regulatory status of the
Companys product candidates, such as the Companys expectations and plans regarding regulatory submissions for and the timing and conduct of clinical trials of DEXTENZA for the treatment of post-surgical ocular inflammation and
pain, including our expectations regarding the resubmission of the NDA and potential FDA approval, DEXTENZA for the treatment of allergic conjunctivitis, DEXTENZA for the treatment of inflammatory dry eye disease and OTX-TP for the treatment of
glaucoma and ocular hypertension, the ongoing development of the Companys sustained release hydrogel depot technology, the potential utility of any of the Companys product candidates, potential commercialization of the Companys
product candidates, the potential benefits and future operation of the collaboration with Regeneron, including any potential future payments thereunder, the sufficiency of the Companys cash resources and other statements containing the words
anticipate, believe, estimate, expect, intend, goal, may, might, plan, predict, project, target,
potential, will, would, could, should, continue, and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform
Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties that could cause the
Companys clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to
the timing and costs involved in commercializing ReSure
®
Sealant or any product candidate that receives regulatory approval, the initiation and conduct of clinical trials, availability of data
from clinical trials and expectations for regulatory submissions and approvals, the Companys scientific approach and general development progress, the availability or commercial potential of the Companys product candidates, the
sufficiency of cash resources and need for additional financing or other actions and other factors discussed in the Risk Factors section contained in the Companys reports on file with the Securities and Exchange Commission,
including the Risk Factors filed on
Form 8-K
on November 29, 2016. In addition, the forward-looking statements included in this report represent the Companys views as of the date hereof. The
Company anticipates that subsequent events and developments will cause the Companys views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically
disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Companys views as of any date subsequent to the date hereof.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
OCULAR THERAPEUTIX, INC.
|
|
|
|
|
Date: February 22, 2017
|
|
|
|
By:
|
|
/s/ W. Bradford Smith
|
|
|
|
|
|
|
W. Bradford Smith
Chief Financial
Officer
|
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Sep 2023 to Sep 2024